Cortechs.ai | Cortechs.ai licenses technology patents from the University of California San Diego (UCSD)

Cortechs.ai licenses technology patents from the University of California San Diego (UCSD)

Technology derived from UCSD researchers to further develop new volumetric imaging products     

(SAN DIEGO) September 11, 2019 – Cortechs.ai, the leader in AI-based brain image quantification, has announced that it has entered into licensing agreements with the University of California San Diego (UCSD), allowing the company to utilize several technologies focused on expanding the role of volumetric magnetic resonance imaging (MRI) in clinical practice.

“These technologies out-licensed from UCSD significantly expand our IP portfolio and will contribute to further development of our flagship product, NeuroQuant® as well as more broadly grow our quantitative MRI focused product lines,” said Dr. Chris Airriess, CEO of Cortechs.ai. “We are excited about the improvements these new technologies will bring to radiology workflow and, most importantly, to patient care in general.”

The technologies licensed from UCSD will allow Cortechs.ai to utilize the specific systems, methods, and software needed to better quantify communications pathways within the brain as well as accurately pinpoint regions of pathology as part of an automated processing stream. Technologies ready for implementation and sub-licensing include advanced techniques for image distortion correction due to magnetic field inhomogeneities, as well as active correction for patient movement in the scanner, which is critical for imaging of some patient populations.

These in-licensed technologies will help Cortechs.ai drive the ongoing evolution of current flagship products, NeuroQuant, LesionQuant™ and PETQuant™, as well as partner with other companies to bring novel AI-based solutions to the volumetric imaging space.

About Cortechs.aiCortechs.ai develops and markets breakthrough medical device software solutions capable of automatically segmenting and quantifying brain structures, making quantitative analysis of the human brain a routine part of clinical practice. Cortechs.ai’ cutting-edge brain imaging analysis provides neurologists, radiologists and clinical researchers worldwide with a convenient and cost-effective means to quantify brain structures to help assess a variety of neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma and brain development abnormalities. Please visit cortechs.ai for further information and follow us on Twitter, LinkedIn and Facebook.

###

 

More Resources

03/13/2026

Cortechs Cares: Community Impact and Volunteer Efforts in 2025

Cortechs Cares highlights how our team gave back in 2025 through community volunteer efforts, including an Alzheimer’s Walk and holiday toy drive.

03/11/2026

OnQ™ Prostate: Bringing Quantitative MRI to Prostate Imaging

Advancing prostate MRI with quantitative diffusion biomarkers. OnQ™ Prostate brings objective RSI-based insights to support data-driven cancer evaluation.

03/04/2026

Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies

NeuroQuant® Lesion Surveillance will be integrated into the Siemens Healthineers Digital Marketplace to advance quantitative brain imaging worldwide.

02/25/2026

Cortechs.ai Announces MFDS (KFDA) Approval of Global-Leading NeuroQuant® V5 Platform in South Korea

MFDS approves NeuroQuant® V5 in South Korea, expanding AI-driven volumetric neuroimaging and clinical decision support.

02/24/2026

Financial Conflict Of Interest Policy Applicable To NIH Awards

02/20/2026

NeuroQuant® PET: FDA 510(k)-Pending Advancement in Molecular Dementia Imaging

FDA 510(k)-Pending NeuroQuant® PET delivers automated, standardized quantification for amyloid, tau, and FDG imaging in dementia care.
Scroll to Top